The association between fasting plasma glucose variability and incident eGFR decline: evidence from two cohort studies

Table 7 HRs and 95% CIs of incident eGFR decline ≥ 40% according to each unit increase in FPG variability measures in pooled data of Tehran Lipid and Glucose Study and Multi-Ethnic Study of Atherosclerosis cohorts

Variability measures	Model 1		Model 2		Model 3		Model 4
Variability measures	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
SD
With diabetes	1.01(1.00–1.01)	0.054	1.00 (0.99–1.01)	0.767	1.00 (1.00–1.01)	0.175	1.00 (0.99–1.01)	0.881
Without diabetes	1.06(1.01–1.11)	0.010	1.05(1.01–1.10)	0.025	1.05 (1.01–1.10)	0.024	1.05 (1.01–1.10)	0.025
CV
With diabetes	1.01 (1.00–1.02)	0.147	1.00 (0.99–1.01)	0.799	1.00 (0.99–1.02)	0.394	1.00 (0.99–1.02)	0.725
Without diabetes	1.05(1.01–1.09)	0.020	1.04 (1.00–1.09)	0.038	1.05 (1.00–1.09)	0.030	1.05 (1.00–1.09)	0.030
ARV
With diabetes	1.01(1.00–1.01)	0.026	1.00 (1.00–1.01)	0.411	1.00 (1.00–1.01)	0.105	1.00 (1.00–1.01)	0.590
Without diabetes	1.02(0.99–1.06)	0.248	1.02 (1.09–1.06)	0.231	1.02 (0.98–1.05)	0.323	1.02 (0.98–1.05)	0.343
VIM
With diabetes	1.00 (1.00–1.01)	0.438	1.00 (0.99–1.01)	0.806	1.00 (0.99–1.01)	0.825	1.00 (0.99–1.01)	0.580
Without diabetes	1.05(1.01–1.10)	0.025	1.05 (1.00–1.10)	0.043	1.05 (1.00–1.10)	0.032	1.05 (1.00–1.10)	0.032

Model 1: adjusted for age and sex at baseline (phase 2)
Model 2: Model 1 + marital status, education, ever smoking, prevalent CVD, physical activity, anti-diabetic drug use, anti-hypertensive drug, lipid-lowering drug, BMI, WC, SBP, DBP, eGFR, and FPG at baseline (phase 2)
Model 3: Model 1 + marital status, education, ever smoking, prevalent CVD, and physical activity at baseline (phase 2), and anti-diabetic drug use, anti-hypertensive drug, and lipid-lowering drug over phases 2–4, and average BMI, WC, SBP, DBP, and eGFR over phases 2–4
Model 4: Model 3 + average FPG

ISSN: 1471-2458